Neuromyelitis Optica Spectrum Disorders Clinical Trial
Official title:
A Phase I Clinical Trial of BAT4406F Injection on the Safety, Tolerability, and Pharmacokinetics in Patients With Neuromyelitis Optica Spectrum Disorders
This study is a phase I clinical study of the safety, tolerability, and pharmacokinetics of BAT4406F injection in patients with neuromyelitis optica spectrum disorders.
This is a Phase 1, open-label, dose-escalation study in NMOSD patients in which subjects will receive BAT4406F injection via intravenous infusion. A 3 + 3 design will be utilized to define a maximum tolerated dose (MTD). The overall objective is to assess the safety, tolerability, and pharmacokinetics of BAT4406F injection in NMOSD patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02836327 -
Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
|
N/A | |
| Not yet recruiting |
NCT06068829 -
Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders
|
||
| Recruiting |
NCT05204459 -
MS-ResearchBiomarkerS
|
||
| Completed |
NCT03350633 -
Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
| Completed |
NCT04388072 -
An Diagnostic Cohort on AQP4-Immunoglobulin G Detection Kit
|
||
| Completed |
NCT05871658 -
Efficacy of Electroacupuncture in NMOSD Patients With Pain: Study Protocol
|
N/A | |
| Recruiting |
NCT02021825 -
Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
|
Phase 4 | |
| Recruiting |
NCT06249438 -
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
|
Phase 1 | |
| Not yet recruiting |
NCT06413654 -
A Phase II/III Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03330418 -
A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders
|
Phase 3 | |
| Enrolling by invitation |
NCT04101058 -
Treatment Response Among Chinese Neuromyelitis Optica Spectrum Disorders
|
||
| Enrolling by invitation |
NCT02809079 -
Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients
|
Phase 4 | |
| Recruiting |
NCT02889965 -
The French Multiple Sclerosis Registry
|
N/A | |
| Completed |
NCT02850705 -
The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS)
|
||
| Completed |
NCT04670770 -
An Open Label Study of the Effects of SHR1459 in NMOSDs Patients
|
Phase 2 | |
| Not yet recruiting |
NCT06212245 -
A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
|
Phase 4 | |
| Completed |
NCT03062579 -
A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05730699 -
Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)
|
Phase 3 |